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conducted in 12 sites in Brazil to evaluate resource utilization in unresectable stage
III and IV metastatic melanoma patients diagnosed or relapsed between 2008-2009.
Frequencies of resources utilization were assessed and multiplied by unit costs,
obtained by SIA-SUS (Outpatient Information System) for public health care costing
and by CBHPM-2005 (Brazilian Hierarchy Classification of Medical Procedures) for
private. RESULTS: Of 165 total patients eligible for the study, 119 (57 private sector
and 62 public sector) received systemic therapy outside of clinical trials and were
therefore eligible for the resource utilization analysis. Across three lines of therapy,
52.9% also received at least one surgery, and 27.7% also received radiotherapy.
While receiving systemic therapy, 29.4% were hospitalized, 13.4% had an emer-
gency room visit, 28.7% had an outpatient visit, and 10.1% had a transfusion. A
similar proportion received surgery in the private and public health sector (56.1%
and 50.0%, respectively), with mean costs USD278 (95%CI USD192-365) and USD437
(95%CI USD322-553), respectively. Hospitalizations were more common in the pri-
vate sector (45.6%) than the public sector (14.5%). The duration of hospitalization
among private patients had a mean duration of 8.7 days per month compared to 3.6
days. Mean costs of hospitalizations were USD1,697 (95%CI USD1,020-2,239) in the
private sector and USD1,332 (95%CI USD821-1,842) in the public. CONCLUSIONS: In
this real-world study in different regions in Brazil, per-patient medical costs in
advanced melanoma patients were higher in the private sector than the public
sector due to both higher unit cost per resource used and greater utilization of
hospitalization.
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OBJECTIVES: Clinical data supports the use of molecular profiling (MP) to inform
therapeutic decisions. In particular, evidence suggests the selection of pharmaco-
therapy for metastatic colon cancer (mCRC) patients could be further improved by
enhancing biomarker informed decision-making. While the clinical data is com-
pelling, our objective was to explore the economic consequences of adopting a
commercial MP approach with accompanying therapeutic recommendations
(Caris Target Now™) from a payer perspective via a detailed cost-offset model.
METHODS: Therapeutic recommendations based on a MP approach were com-
pared to current treatment patterns to determine the change in treatment mix and
associated treatment costs. Biomarker selection was based on a systematic review
of the literature and grading the evidence to support clinical benefit for a specific
treatment choice. Oncologists were interviewed to inform and validate modeled
treatment pathways based on patterns of biomarker expression in the patient’s
tumor. Biomarkers evaluated include: BRAF, KRAS, NRAS, PI3KCA, PTEN, EGFR,
TOP1, ERRC1, TS, and EML4-ALK. RESULTS: In our model, approximately 29% of
patients who test positive for response to EGFR inhibitor therapies, under current
clinical treatment protocol, have additional biomarkers with compelling data to
suggest non-responsiveness. These same patients display biomarkers indicating
potential benefit of other drugs. Biomarker-associated change in therapy as sug-
gested by MP, yielded an annual savings of $7.3k per mCRC patient. The adoption of
this MP service provided net cost-benefit; treatment costs avoided were substan-
tially higher (232%) than the testing cost. CONCLUSIONS: Molecular profiling, in-
cluding analysis of oncoproteins, gene expression and specific gene mutations,
may add significant economic value to the treatment of cancer patients by direct-
ing treatments to those most likely to respond. The cost-offsets associated with
biomarker-based therapy choice lead to more rational use of high-cost drugs. Im-
plementing therapy for mCRC based on a multi-biomarker, decision-support ap-
proach may have potential to improve patient care and decrease costs.
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OBJECTIVES: A relative value analysis (RVA) of first-line treatments for chronic
myeloide leukemia, dasatinib and imatinib, was performed from the Spanish Na-
tional Health System perspective.METHODS:A decision model was built according
to the European Leukemia Net recommendations. Response and tolerance were
assessed based on trial outcomes. The model was run for 1,000 patients initiated on
dasatinib (100mg, QD) or imatinib (400mg QD). Dose adjustments or treatment
switches for limited response or intolerance were allowed. Ten different cost levers
were identified for four sources of value (response, adverse event, adherence and
monitoring). Total cost (€, 2012) was estimated over 5-years, with an annual 3%
discount rate, by sum of the cost levers and drugs cost (ex-factory price with 7.5%
mandatory rebate). Data sources included literature, health costs database and
expert opinion. Sensitivity analyses (SA) were performed. RESULTS: The final in-
cremental total cost of dasatinib compared to imatinib, resulting from the RVA was
€3,355 per patient per year. Difference in drug cost of dasatinib is estimated to be
€11,363/patient/year compared to imatinib. Monitoring and treatment of adverse
events increased costs by €36/patient/year with dasatinib. Dasatinib, however, is
associated with savings in other costs: cases of low dose regimens saved €65/
patient/year. Switching for limited response or intolerance decreased costs by up to
€6,819 and €563/patient/year respectively, with dasatinib. Costs of non-adherence
and other additional management were reduced €466 and €132/patient/year with
dasatinib vs imatinib. The SA showed further reductions in the incremental cost of
dasatinib when longer term cost savings were included or the share of imatinib
patients after intolerance or limited response was increased. CONCLUSIONS: The
incremental drug cost of dasatinib vs imatinib €11,363 per patient/year (31%) is
reduced to €3,355/patient/year (9%) if the cost consequences of the events over 5
years are considered.
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OBJECTIVES: To conduct a cost-consequence analysis of the treatment of sub-
ependymal giant cell astrocytoma (SEGA) secondary to tuberous sclerosis complex
(TSC) with everolimus under the Brazilian public health care system (SUS) and
societal perspectives. METHODS: A cost-consequence analysis was developed to
compare the treatment of SEGA secondary to TSC with everolimus and current
treatment options, based on the Phase II trial of everolimus in the indication.
Population included patients above 3-years of age. Direct medical costs were esti-
mated from the perspective of the SUS, while direct medical and productivity costs
were estimated from a societal perspective. Model inputs for SEGA growth, hydro-
cephalus and seizure controls were based on the trial results. Use of resources and
unit costs were obtained from the national and international literature and admin-
istrative databases. Analysis included costs for managing adverse events on
everolimus treatment. Costs are expressed in 2011 Reals. Results are presented in
terms of incremental cost per patient with everolimus, considering scenarios with
and without seizure control. Time horizon was set in two years and no discount
was applied. Univariate sensitivity analysis was performed. RESULTS: The incre-
mental cost of treatment with everolimus was R$49.790/patient and R$40.131/pa-
tient from the perspectives of SUS and society, respectively. Patients treated with
everolimus did not experience complications of SEGA growth, and did not undergo
surgery to remove the SEGA. If improved seizure control is considered, the incre-
mental cost is reduced to R$48.949/patient and R$39.290/patient from SUS and
societal perspectives, respectively. Results were most sensitive to drug cost and
average dose. CONCLUSIONS: The incremental cost per patient with everolimus in
SEGA/TSC can be used as a simple instrument in the HTA process in Brazil, indi-
cating value for money in the comparison of current invasive interventions with
novel drug therapy affecting both patients and their caregivers.
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OBJECTIVES: Cervical cancer (CC) remains the leading cause of cancer death
among Colombian women. Human papillomavirus (HPV) 16 and 18 infection is
associated with CC while HPV 6 and 11 are related to genital warts (GW). Currently
are available 2 vaccines against HPV. Bivalent protects against carcinogenic geno-
types and tetravalent also protects against genotypes GW associated. We present
the cost-effectiveness evaluation of the introduction of two vaccination strategies
in Colombian women taking into account the current screening program.
METHODS: We designed a Markov model, which simulates the natural history of
CC and GW in a cohort of women. The occurrence parameters were extracted and
validated with a literature review and national databases. The costs were esti-
mated from costing of standard cases. We estimated the impact of the introduction
of bivalent and tetravalent HPV vaccines. We compared the different strategies in
a competitive scenario and built the ICERs. A sensitivity analysis was carried out.
RESULTS: In a cohort of 430,859 women followed for the entire life without vacci-
nation or screening programs 15,284 CC cases and 18,275 GW episodes may occur.
The CC would cause 4733 deaths. The screening program would prevent 3015 CC
deaths. Either vaccination alternatives prevents 1958 CC deaths additional to
screening program, and they are cost-effective when compared against non-vac-
cination. In a competitive analysis, vaccination with bivalentscrenning is domi-
nated while vaccination with tetravalentscreening is cost-effective (ICER per
DALY averted US $ 1239). The results are sensitive to changes in the parameters of
progression of neoplastic disease. CONCLUSIONS: Economic evaluation of HPV
vaccines in Colombian scenario shows that bivalent vaccination is a dominated
strategy, while tetravalent vaccination is cost-effective at a willingness to pay less
than 1 GDP per capita per DALY averted. The relative advantage of tetravalent is
due to avoided of costs and DALYs due to GW.
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OBJECTIVES: Denosumab reduced SREs versus zoledronic acid in a phase 3 trial,
but without significant differences in overall survival, disease progression, or seri-
ous adverse events. The cost-effectiveness of denosumab versus zoledronic acid in
mPC was assessed from a UK payer perspective. METHODS: A Markov model esti-
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mated quality-adjusted life-years (QALYs), number/costs of SREs, and drug/admin-
istration costs for mPC patients receiving denosumab or zoledronic acid for 27
months (trial timeframe) and 60 months. List prices were used in the base case. A
generic zoledronic acid price (53%  list price, per data for now-generic bisphos-
phonates) and discounted prices (–30%) were used for both denosumab and zole-
dronic acid in scenario analyses. Clinical inputs reproduced trial outcomes. QALYs
were estimated via utility weights to time spent in health states (no SRE; SRE;
post-SRE; death). SRE costs and utilities were literature-based. RESULTS: Over 60
months, denosumab resulted in fewer SREs (–0.398), more QALYs (0.0096), and
lower SRE-related costs (–£790). The costs/QALY (drug costs; total costs) over 60
months in the list price scenario (list price for both agents), in the generic zole-
dronic acid after May 2013 pricing scenario, and in the scenario with both agents
discounted after May 2013, were £164,502 (£2369; £1579), £214,707 (£2851;
£2061), and £98,124 (£1732; £942), respectively. Similar results were found over
27 months. CONCLUSIONS: The incremental cost/QALY gained with denosumab
versus zoledronic acid exceeded the traditional £30,000 threshold, thus raising
important questions about denosumab’s health-economic value in mPC.
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OBJECTIVES: Approximately 60% of breast cancer cases are a hormone sensitive.
Tamoxifen (TAM) is most widely used treatment of hormone-dependent breast
cancer. In the last decade, TAM has been surpassed by more effective, but more
expensive Aromatase Inhibitors (AI), new generation of estrogen inhibitors. In Can-
ada, mono and sequential strategies of AI and TAM for treating ER early breast
cancer patients are used widely. Meanwhile, practitioners have not come to a
consensus yet regarding the optimal cost-effective hormone therapy strategy. The
objective of study to assess cost-effectiveness of four hormone strategies (mono
and sequential TAM and AI) currently used for treating ER early breast cancer
patients from the Canadian health care perspective. METHODS: We performed a
cost-effectiveness analysis using a Markov model from a societal perspective with
a lifetime horizon. The base case involved 65-year-old ER hormone sensitive
women with early breast cancer. Probabilistic sensitivity analysis was used to in-
corporate parameter uncertainties. Expected value of perfect information was per-
formed to identify future research directions. Outcomes were quality-adjusted life
years (QALYs) and costs. RESULTS: AI-TAM sequential strategy is dominant be-
cause it is more effective and less costly. Next dominant strategy is TAM-AI, AI
monotherapy is more effective but more costly than standard TAM monotherapy.
AI monotherapy, TAM-AI and AI-TAM sequential therapies reduce recurrence by
8.1%, 5.9% and 5.6% compared to TAM monotherapy. Additional QALY gained from
using new therapies were 0.06 QALYs for AI, 0.08 QALY’s for TAM-AI and 0.16
QALYs for AI-TAM therapies. Using AI monotherapy increased total expected dis-
counted cost by CAD $302 per patient compared to TAM monotherapy, while using
sequential therapies reduced total cost by CAD $62 TAM-AI and CAD $481 for
AI-TAM. CONCLUSIONS: In postmenopausal ER women with hormone sensitive
early breast cancer, adjuvant AI-TAM sequential therapy may be cost effective
from the Canadian health care system perspective.
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OBJECTIVES: Effectiveness of rituximab maintenance treatment among patients
with relapsed follicular lymphoma (FL) has been established in a randomised trial
(EORTC20981). Although trials have been accepted as the golden standard for ef-
fectiveness, results might not be generalisable to real-world patient populations.
Therefore, outcomes research was conducted to calculate real-world cost-effec-
tiveness of second line rituximab maintenance compared to observation in FL
patients in the Netherlands. METHODS: Two Dutch population-based registries
(PHAROS and HemoBase), obtained data on patient characteristics, treatment, and
resource utilisation of patients diagnosed with FL in the past 20 years. Patients
responding to second line chemotherapy were included in the observation or
maintenance group. A Markov model was applied to calculate real-world
cost-effectiveness. RESULTS: Out of 735 FL patients included in the registries, this
study allocated 57 and 49 patients to the observation and maintenance group,
respectively. Median age was similar in both groups (61 years). Differences between
the groups were found for second line treatment with rituximab (77% and 92% in
the observation and maintenance group p0.05) and years since diagnosis
(p0.01). The maintenance group showed higher 3-year overall survival (75% ver-
sus 63%) and longer time till next treatment (p0.01). Compared to the trial, real-
world patients were older and less often diagnosed with stage IV. Real-world pre-
scription of rituximab was comparable to the trial although cycles were prescribed
more frequent. Daily practice data combined with trial efficacy resulted in cost-
effectiveness ratios between €3,614 and €5,246 per life year gained and €3,555 and
€5,156 per quality-adjusted life year. CONCLUSIONS: Real-world FL patients were
not identical to trial patients emphasising the importance of studying real-world
data. However, findings from non-randomised groups should be analysed with
caution, since observed dissimilarities between the groups suggested the represen-
tation of different types of patients. Nevertheless, real-world cost-effectiveness for
second line rituximab maintenance was favourable.
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OBJECTIVES: Maintenance treatment with Rituximab (MabThera) has been shown
a cost-effective and / or cost-saving treatment option, when compared with alter-
native treatment strategies for treating patients with Non-Hodgkins Lymphoma
(NHL) in several countries. The objective of this study is to identify whether main-
tenance with Rituximab in first line NHL patients represents a cost-effective treat-
ment option for the Greek Healthcare system. METHODS: A cost-effectiveness
Markov model that compared maintenance with Rituximab versus observation
was applied after adapting for local cost data from published sources. Clinical data
were derived from PRIMA and EORTC 20981. RESULTS: Patients treated with Ritux-
imab remained in Progression Free state for an additional 1.91 years and displayed
an additional 1.61 QALYs versus observation. Mean Total Cost per patient in the
Rituximab maintenance arm was calculated at €79,721 versus €67,928 in the obser-
vation arm. Mean total cost of PFS including the cost of Adverse Events was €71.95
for the Rituximab group and €57.44 for the observation group. Mean Supportive
Care costs for the Progression-Free state were € 18,193 for patients on Rituximab
and €20,168 for patients on observation. Mean supportive care cost of progression
was € 7,766 for the Rituximab group and €10,483 for the observation group. ICERs for
Rituximab maintenance were €8,679 per QALY gained and €7,866 per LYG gained,
which are both below the common cost-effectiveness thresholds used by Health
Technology Assessment (HTA) agencies worldwide. CONCLUSIONS: Maintenance
treatment with Rituximab is clinically more effective and economically more cost-
effective than existing treatments for patients with NHL in the Greek health care
setting. Full reimbursement of Rituximab maintenance treatment for patients with
NHL by Social Security Funds would constitute an effective use of their – scarce –
resources.
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OBJECTIVES: In the UK, prostate cancer is the most commonly-occurring cancer in
males; it has an incidence rate of 103 per 100,000. First-line therapy for patients
with advanced prostate cancer is commonly a luteinising hormone-releasing hor-
mone (LHRH) agonist. Degarelix is a testosterone-ablating therapy that acts as
gonadotrophin-releasing hormone (GnRH) antagonist. It induces a decrease in both
testosterone and prostate-specific antigen (PSA) levels, without the initial testos-
terone surge which can be associated with LHRH agonist therapies such as leupro-
relin, goserelin and triptorelin. A previous model assessing the cost-effectiveness
of degarelix was published by Lu et al (2011). However, only limited data were
available at the time and here we present a model based on longer term data.
METHODS: A cost-utility model using a cohort state transition structure was de-
veloped to assess the cost effectiveness of degarelix. The 5-year data informing the
model was derived from the Phase III clinical trials (CS21 and CS21a). Advisory
boards conducted with UK clinicians informed the model structure. Patients trans-
ferred through disease states according to their PSA progression – identified by
clinicians as a key indicator of progression to second-line treatment. Adverse
events for which there were statistically significant differences were also included
in the model. A scenario analysis was undertaken where PSA progression was
assumed to be equal for degarelix and leuprorelin, although data indicate a lower
risk with degarelix. RESULTS: Degarelix showed a reduction in costs (£5,152) and
increase in QALYs (0.24) when compared to leuprorelin in the base case. In the
scenario analysis, treatment with degarelix was also dominant. CONCLUSIONS:
Updated modelling undertaken with the most recent data indicates that treatment
with degarelix is dominant – this remains the case when it is conservatively as-
sumed, that PSA progression is not important, contrary to what was informed by
clinicians, and seen in the trial data.
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OBJECTIVES: Personalized medicine tries to select specific subpopulation of pa-
tients by biomarkers to refine therapeutic algorithms. We have performed a cost-
effectiveness analysis to assess incremental cost-effectiveness ratio (ICER) per ra-
diological response (RR) for cetuximab or panitumumab based scheduled as 1st line
therapies for metastatic colorectal cancer (mCRC) patients in Spain. METHODS:
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